Abstract
The aim of the NeoVitaA Trial is to assess the role of postnatal additional high-dose oral vitaminA supplementation for 28days in reducing Bronchopulmonary dysplasia (BPD) or death in extremely low birth weight (ELBW) infants at 36weeks postmenstrual age (PMA). All infants (both intervention and control group) will be provided with basic vitaminA (1000 IU/kg/day) in addition to trial intervention.In this short communication, we will give an up-date on obstacles, challenges as well as perspectives and potential solutions when putting into place amulticenter, double-blind, randomized trial in this cohort of extremely susceptible infants.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
